No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
about
Glycaemic Effects of Non-statin Lipid-Lowering TherapiesDesign and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO IIPCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.Alirocumab for the treatment of hypercholesterolaemia.Alirocumab for the treatment of hypercholesterolemia.Pharmacological management of diabetic dyslipidemia.Bococizumab for the treatment of hypercholesterolaemia.PCSK9 inhibition: the dawn of a new age in cholesterol lowering?Can LDL cholesterol be too low? Possible risks of extremely low levels.Investigational therapies for hypercholesterolemia.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.PCSK9 and carbohydrate metabolism: A double-edged sword.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination.Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.Unexplained reciprocal regulation of diabetes and lipoproteins.Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractLarge-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke
P2860
Q28070152-13BC855E-FDC9-49F9-B1FF-F56FE559922DQ33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7Q33835866-CDA57797-E670-4CAA-8913-E0135498E6AAQ37607330-3E2C06FD-EAB6-4280-8730-5148269FD3B6Q38664321-1BB2D7F8-FAAD-47EC-970D-7DAA325DB1D8Q38843982-ECA236B9-2440-447B-835D-662E45172B60Q38917894-5558842B-FFF2-4865-85CC-1E37BD025AD7Q39015072-ABE41565-76CB-42AF-83AE-D8B15C443E4AQ39035931-9C979461-D8BF-47D6-9222-2D476CC02EF1Q39057046-3894319E-F17C-46C9-883A-F5E2FB0E244CQ39179689-E308D600-1E75-4F54-9387-B33634664822Q39215123-F433E940-0F36-447B-A04D-66554A3C7FDBQ39420208-4F5AA016-3A1D-471C-9242-11011EC03744Q39453691-3FA24598-C867-4298-9824-0030E5060FC3Q42333207-511A349D-D216-496A-A877-2D930D6F75B3Q44847105-0D8CFBA9-7547-44F0-8337-B3828D45D03FQ47419614-1F7D7139-96DA-4729-9454-9F2F5850E2FFQ47567094-ED9286A3-BC73-4A05-812F-B44B40AC0A28Q48254766-BE65E380-5544-489B-BA2F-9C0830DA5409Q49972440-31445071-5401-491F-90F0-632042F9BACEQ50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3Q50271173-3081677E-5E7C-4E52-8B90-A8052C7B2955Q51746011-E41B8C62-4748-4392-A0F1-193DAA6905F5Q52721601-D6CAE7B5-1B91-4E8D-B0FD-9400A96D4B64Q53644756-B38739DC-5643-42D8-98CB-A2A28F4CECBFQ53690107-C7AB114E-D65B-4DD0-B937-F10D666FBD38Q54942141-3A385EC4-ECFD-4529-A3AC-77AB2D586E7AQ55259756-5B28276C-5B2B-47EF-9760-827BD334BA8FQ56984696-1B9452A2-788E-47AC-B67B-E64C99415E65Q57177843-3953898A-0523-4BE5-B752-E430307C4A2A
P2860
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@en
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@nl
type
label
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@en
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@nl
prefLabel
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@en
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@nl
P2093
P2860
P356
P1476
No effect of PCSK9 inhibitor a ...... om 10 ODYSSEY Phase 3 studies.
@en
P2093
Bertrand Cariou
Dirk Müller-Wieland
Helen M Colhoun
Henry N Ginsberg
Jennifer G Robinson
Laurence Merlet
Lawrence A Leiter
Marie T Baccara-Dinet
Robert H Eckel
Robert Pordy
P2860
P304
P356
10.1093/EURHEARTJ/EHW292
P577
2016-07-26T00:00:00Z